• Wenjie Li, Yanjun Zhao, Hongjun Zhang, Wenying Zheng, Ruixuan Wang, and Xing Gu.
• Department of Respiratory and Critical Care Medicine, Xi'an Chest Hospital, Chang'an District, Xi'an, Shanxi, China.
• Medicine (Baltimore). 2023 Oct 6; 102 (40): e34990e34990.

BackgroundTo investigate the association between tumor mutational burden (TMB) and the therapeutic effect of Programmed Death 1/Programmed Death Ligand 1 inhibitors in non-small cell lung cancer.MethodsFour electronic databases, PubMed, Embase, Web of Science, and Cochrane Library, were searched on May 10, 2023, and no time limitation was applied. Analyses were performed using STATA17.0. We assessed the methodological quality of each randomized controlled trial using the Newcastle-Ottawa scale.ResultsAfter exhaustive database search and rigorous screening, 10 studies were included in the meta-analysis. Our findings indicate that high TMB significantly improves progression-free survival but reduces overall response rate. The overall survival was not significantly different between the high and low TMB groups. No significant publication bias was observed.ConclusionHigh TMB serves as a potential predictive biomarker for improved progression-free survival and reduced overall response rate in patients with non-small cell lung cancer treated with programmed death 1/programmed death ligand 1 inhibitors. However, its predictive value in overall survival requires further investigation.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…